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osting by EAbstract Objective of present study is to evaluate the possible role of clopidogrel in improving gly-
cemic indices and oxidative stress in patients with type 2 diabetes.
This study was performed on 42 uncontrolled type 2 diabetic patients at the specialized center for
Endocrinology and Diabetes, Al-Rasafa Directorate of Health, Baghdad. All of the patients were
treated with (glibenclamide 5 mg at morning) and randomized into two groups: the ﬁrst group
includes 22 patients treated with clopidogrel tablets (75 mg/day) for 2 months; the second group
includes 20 patients treated with a placebo formula (sodium bicarbonate 200 mg/day) for the same
period. Treatment with clopidogrel produced signiﬁcant improvement (P< 0.05) in fasting serum
glucose (FSG), fasting serum insulin level, quantitative insulin sensitivity check index (QUICKI);
and oxidative stress markers: serum malondialdehyde (MDA) and serum reduced glutathione
(GSH) compared to their baseline levels. There was signiﬁcant elevation (P< 0.05) in both FSG
and fasting serum insulin and the MDA level with signiﬁcant reduction (P< 0.05) in QUICKI
of placebo group compared to their baseline levels. However, clopidogrel produced signiﬁcant ele-
vation (P< 0.05) in AST and ALT levels but placebo formula caused no signiﬁcant alteration
(P> 0.05) in the serum levels of these two enzymes.
In conclusion the treatment with clopidogrel improved glycemic indices and reduced oxidative
stress in patients with type 2 diabetes.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.7902625273.
(M.A. Taher).
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lsevier1. Introduction
Type 2 diabetes accounts for about 90–95% of those with dia-
betes. Previously it was known as non-insulin dependent diabe-
tes or adult onset diabetes. It involves insulin resistance and
relative insulin deﬁciency as seen in type 1 diabetes (Flower,
2007). Insulin resistance is strongly associated with obesity
and physical inactivity, and several mechanisms mediating this
interaction have been identiﬁed. A number of circulating hor-
mones, cytokines, and metabolic fuels, such as free fatty acids
(FFA) originate in the adipocytes and modulate insulin action.
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deep subcutaneous adipose depot, leads to large adipocytes
that are themselves resistant to the ability of insulin to sup-
press lipolysis; this results in increased release and circulating
level of FFA and glycerol, both of which aggravate insulin
resistance in skeletal muscle and liver (Stumvoll et al., 2005).
These FFA can inﬂuence insulin signaling pathway by activat-
ing of several serine/thionine kinases, reducing the tyrosine
phosphorylation on insulin receptor substrate (IRS) and
impairing IRS/phospho-inositide-3-kinase pathway (Kow-
alska, 2007; White, 2002). Recently, several groups provided
strong evidence to support the concept of adipose tissue as
an endocrine organ producing cytokines which modulate glu-
cose homeostasis (Saltiel and Kahn, 2001). Tumor necrosis
factor alpha (TNF-a) is a cytokine produced by adipocytes
that may contribute to the development of insulin resistance
in obesity. TNF-a can impair insulin action on glucose metab-
olism and increase lipolysis. At the molecular level, TNF-a in-
creases serine phosphorylation of IRS-1 and down regulates
GLUT-4 expression, thereby contributing to insulin resistance
(Saltiel and Kahn, 2001; Kahn and Flier, 2000).
Oxidative stress plays a central role in the onset of diabetes
mellitus as well as in the development of vascular and neuro-
logical complications of the disease. The source of oxidative
stress is a cascade of reactive oxygen species (ROS) leaking
from mitochondria and this process has been associated with
the onset of type 1 diabetes via the apoptosis of pancreatic
B-cells and the onset of type 2 diabetes via insulin (Phillips
et al., 2004). Hyperglycemia in diabetic patients leads via sev-
eral mechanisms that, include increased polyol pathway ﬂux
increased intracellular advanced glycation end product forma-
tion, activation of protein kinase C (PKC) and increased hex-
oseamine pathway ﬂux, to multiple biochemical squeal aimed
to an increased production of ROS (Bonnefont-Rousselet,
2002).
Clopidogrel is a potent antiplatelet drug which belongs to
thioenpyridine derivatives. It selectively inhibits the binding
of ADP to its platelets receptor and the subsequent ADP med-
iated activation of the glycoprotein GP11b/111a complex,
thereby inhibiting platelet aggregation (Richter et al., 2004).
Type 2 diabetes is a state of increased plasma coagulability.
The platelet aggregatability is increased and ﬁbrinolytic capac-
ity is reduced. Antiplatelet therapy, notably use of aspirin, has
been shown to be effective in reducing cardiovascular events,
but clopidogrel has been appeared to be more potent than
aspirin in reducing cardiovascular events in patients with type
2 diabetes (Mooradian, 2003). The protective effects of clopi-
dogrel on oxidant damage in a rat model of acute ischemia
have been studied. The results of this study revealed that clop-
idogrel prevents the increase in MDA level and the decrease in
GSH level and SOD activity caused by the ischemia–reperfu-
sion in both tissue and plasma samples (Kanko et al., 2005).
MDA is known as the main parameter showing the level of
lipid peroxidation process induced by oxidative stress. The pri-
mary antioxidative enzyme, SOD and GSH, powerful antioxi-
dants are among the ﬁrst line of defense mechanism against
oxidative stress (Cheeseman and Slater, 1993). Clopidogrel
also reduces levels of serum hs-CRP and TNF-a in patients
with non-ST segment elevation acute coronary syndrome. Ele-
vated levels of markers for inﬂammation (such as CRP and
TNF-a) have been associated with increased risk for ﬁrst and
recurrent cardiovascular events (Chen et al., 2006). Clopido-grel is considered not just an antiplatelet agent but a drug with
pleiotropic effects, which contribute to its long term beneﬁt
(Angiolillo et al., 2006).2. Materials and methods
2.1. Chemicals
Glucose, AST and ALT are measured using kits supplied by
Randox, UK. Mogrel (Clopidogrel 75 mg) tablets are pur-
chased from Mission, India. Insulin ELISA kits provided by
DRG International Inc., USA.
2.2. Patients and control subjects
This study was performed on 42 uncontrolled type 2 diabetic
patients at the specialized center for Endocrinology and Diabe-
tes, Al-Rasafa Directorate of Health – Baghdad (24 males and
18 females) with age range (40–68 years), and with mean dura-
tion of diabetes of 5 years.
The selected patients attended the medical center from
November 2007 to May 2008 during their periodic visit seeking
for medical advice concerning their diet modiﬁcation, weight
reduction and drug prescription. The diabetic patients were se-
lected by a senior physician and those patients were diagnosed
as diabetic according to the American Diabetes Association
Criteria [fasting plasma glucose P126 mg/dL (7.0 mmol/L)
or 2 h plasma glucose after oral glucose tolerance test
P200 mg/dL (11.1 mmol/L)] (American Diabetic Association,
2008). All the selected patients have no other prominent path-
ological disorders like hypertension and IHD. The patients
were already treated with ordinary hypoglycemic agent gliben-
clamide, but with poor glycemic control as evidenced by the
abnormal values of fasting plasma glucose.
Patient’s selection and enrollment in the study after their
agreement was performed according to the following exclusion
criteria:
1. Patients with chronic disease like liver, kidney disorder and
cardiovascular complications, or acute infections.
2. Patients with pregnancy or breast feeding are excluded.
3. Patients with history of alcohol consumption are excluded.
4. Patients with history of active pathological bleeding such as
peptic ulcer and intracranial hemorrhage.
5. Patients on insulin therapy or maintained on any type of
anti-oxidant drugs or aspirin.
The selected patients were divided randomly into two
groups:
1. Clopidogrel group: included 22 patients (14 males and 8
females) treated with antiplatelet agent clopidogrel bisulfate
in a dose of one tablet (75 mg) ingested once daily for
2 months in addition to the routinely used oral hypoglyce-
mic agent (glibenclamide 5 mg in the morning).
2. Placebo group B: included 20 patients (10 males and 10
females) were treated with placebo capsules containing
sodium bicarbonate (Liu et al., 1997) in a dose of one cap-
sule 200 mg ingested once daily for 2 months duration, in
addition to the routinely used oral hypoglycemic agent (gli-
benclamide 5 mg at morning). Sixteen healthy control
Volunteers 
(n=58) 



















Figure 1 Distribution of volunteers included in the study.
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patients were selected to evaluate the normal values of the
studied parameters (Fig. 1).
All patients received their treatment for 2 months duration,
and blood samples were collected from them at the beginning
of the study (baseline samples) and after 2 months of starting
treatment to measure the possible change in the studied
parameters (see Table 1).
2.3. Samples collection and preparation
After 12 h fasting, blood samples were collected from all sub-
jects by vein puncture (10 mL), before starting drug treatment
(as baseline sample) and then after 2 months of treatment to
follow the changes in the studied parameters.
The blood was collected in plane tubes and after clotting
was centrifuged at 3000 rpm for 10 min to obtain serum. Fresh
serum was used for the measurement of MDA (biomarker of
lipid peroxidation) and GSH (a biomarker of antioxidant sys-
tem). The remaining serum was stored frozen at 20 C until
analysis was performed.Table 1 Characteristics of control subjects and type 2 diabetic pati
Variable Type 2 d
Number 42
Gender (male/female) 24/18
Age (years) 52.04 ± 7
BMI (kg/m2) 28.28 ± 3
FSG (mmol/L) 9.10 ± 2.
Systolic blood pressure (mmHg) 120.64 ±
Diastolic blood pressure (mmHg) 80.45 ± 0
The data are expressed as mean ± SD.
BMI = body mass index; FSG= fasting serum glucose.2.4. Measurement of serum glucose level
Glucose was determined by enzymatic oxidation in the pres-
ence of glucose oxidase (Barham and Trinder, 1972).
2.5. Determination of serum insulin level
The insulin ELISA kit is a solid phase-enzyme-linked immuno-
sorbent assay based on the sandwich principle (Flier et al.,
1979). The microtiter wells are coated with monoclonal anti-
body directed toward a unique antigenic site on human insulin
molecule. An aliquot of patient’s sample containing endoge-
nous insulin is incubated in the coat well with enzyme conju-
gate, which is an anti-insulin antibody conjugated with
biotin. After incubation the unbound conjugate is washed
off. During the second incubation step streptavidin–peroxidase
enzyme complex binds to biotin–anti-insulin antibody. The
mount of bound horseradish peroxidase (HRP) complex is
proportional to the concentration of insulin in the sample.
Having added the substrate solution, the intensity of color
developed is proportional to the concentration of insulin in
the patient sample with running proper standards of insulin.
Absorbance was measured spectrophotometrically at 450 nm.
The results were expressed as lIU/mL. Serum insulin levels
were determined for the diabetic patients and control subjects.
2.6. Estimation of insulin sensitivity
Insulin sensitivity was determined using the quantitative insu-
lin sensitivity check index (QUICKI) which is calculated from
fasting plasma glucose (FPG) and fasting plasma insulin (FPI)
using the following formula (Katz et al., 2000):
QUICKI ¼ 1=ðlogðfasting insulin lU=mLÞ
þ logðfasting glucose mg=dLÞÞ2.7. Assessment of lipid peroxidation
Determination of lipid peroxidation performed by estimation
of MDA, the degradative by-product of peroxidized lipid after
reaction with thiobarbituric acid (TBA) to form MDA-TBA2
complex, a red chromophore that can be analyzed spectropho-
tometrically depending on the method of Beuge and Aust
(1978). The procedure includes the addition of 1 mL of TBA
reagent [0.375 g TBA, 15 g trichloroacetic acid (TCA) and
2.1 mL of 11.9 N hydrochloric acid, up to 100 mL distilledents.
iabetic patient Healthy control subjects
16
7/9
.31 48.19 ± 6.76
.68 27.07 ± 3.52
87 4.87 ± 0.63
0.70 120.00 ± 1.21
.74 70.75 ± 0.68
Table 2 Effect of 2 months treatment with clopidogrel or with placebo on glycemic control markers (FSG, insulin level and insulin
sensitivity) in diabetic patients taking glibenclamide.
Control (n= 16) Clopidogrel group (n= 22) Placebo group (n= 20)
FSG (mmol/L)
Baseline 4.875 ± 0.159 9.705 ± 0.743*,a 8.415 ± 0.418*,a
After 60 days 7.495 ± 0.532*,b 9.33 ± 0.575*,b
% Change 22.77 10.87
Serum insulin level (mIU/mL)
Baseline 7.177 ± 0.950 11.76 ± 1.00*,a 13.838 ± 0.943*,a
After 60 days 8.981 ± 0.514b 15.277 ± 1.254*,b
% Change 23.63 10.4
Insulin sensitivity (QUIKI)
Baseline 0.364 ± 0.006 0.295 ± 0.007*,a 0.304 ± 0.003*,a
After 60 days 0.326 ± 0.005*,b 0.298 ± 0.004*,b
% Change 10.51 1.97
Data are expressed as mean ± SEM.
n=Number of subjects or patients.
Non-identical superscripts (a, b) within the same group represent signiﬁcant difference (P< 0.05), by paired t-test.
* P< 0.05 with respect to control group, by unpaired t-test.
Table 3 Effect of 2 months treatment with clopidogrel and with placebo on oxidative stress markers (MDA and GSH) in diabetic
patients taking glibenclamide.
Control (n= 16) Clopidogrel group (n= 22) Placebo group (n= 20)
Serum MDA (lmol/L)
Baseline 1.086 ± 0.01 2.38 ± 0.18*,a 2.02 ± 0.14*,a
After 60 days 2.09 ± 0.14*,b 2.31 ± 0.13*,b
% Change 12.18 14.36
Serum GSH (lmol/L)
Baseline 0.273 ± 0.004 0.153 ± 0.01*,a 0.186 ± 0.018*,a
After 60 days 0.205 ± 0.006*,b 0.169 ± 0.008*,a
% Change 34.53 9.19
Data are expressed as mean ± SEM.
n=Number of subjects or patients.
Non-identical superscripts (a, b) within the same group represent signiﬁcant difference (P< 0.05), by paired t-test.
* P< 0.05 with respect to control group, by unpaired t-test.
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heated in water bath at 95 C for 15 min, cooled and centri-
fuged at 3000 rpm in cooled centrifuge for 10 min. Light absor-
bance of clear supernatant was determined at 535 nm. The
MDA concentration is calculated using a molar absorptivity
coefﬁcient of 1.56 · 105 M1 cm1. The results were expressed
as lmol/L.
2.8. Serum glutathione determination
Serum reduced glutathione (GSH) content was determined
according to the method of Ellman (1959), that included the
addition of 0.5 mL of serum to equal volume of 4% sulfosali-
cylic acid and centrifuged in cooled centrifuge for the precipi-
tation of protein, then 0.5 mL of clear supernatant was added
to 4.5 mL of 5,5-dithiobis-(2-nitrobenzoic acid), DTNB re-
agent [0.1 mM of DTNB in 0.1 M phosphate buffer, pH 8].
The absorbance of the solution is measured at 412 nm after2 min. Serum glutathione concentration is calculated using a
molar absorptivity coefﬁcient of 13,600 M1 cm1. The ﬁnal
results were expressed as lmol/L.
2.9. Determination of aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) activities in serum
The activities of AST and ALT were calculated calorimetri-
cally according to the method of Reitman (Reitman and Fran-
kel, 1957).
2.10. Statistical analysis
The results were expressed as mean ± standard error of mean
(SEM) or percent of changes. Student’s t-test was used to
examine the degree of signiﬁcance. P values less than 0.05 were
considered signiﬁcant. The statistical analysis was performed
using Microsoft Excel 2003.
Table 4 Effect of 2 months treatment with clopidogrel and with placebo on hepatic function markers (AST and ALT) in diabetic
patients taking glibenclamide.
Control (n= 16) Clopidogrel group (n= 22) Placebo group (n= 20)
AST (U/L)
Baseline 21.37 ± 1.32 22.73 ± 0.42a 22.7 ± 0.40a
After 60 days 23.23 ± 0.33*,b 22.75 ± 0.37a
% Change 2.2 0.22
ALT (U/L)
Baseline 17.813 ± 0.42 18.14 ± 0.43a 18.15 ± 0.30a
After 60 days 19.27 ± 0.40b 18.4 ± 0.36a
% Change 6.23 1.38
Data are expressed as mean ± SEM.
n=Number of subjects or patients.
Non-identical superscripts (a, b) within the same group represent signiﬁcant difference (P< 0.05), by paired t-test.
* P< 0.05 with respect to control group, by unpaired t-test.
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3.1. Effect of treatment with clopidogrel on fasting serum
glucose, serum insulin level and quantitative insulin sensitivity
check index (QUICKI)
Results presented in Table 2 revealed that the levels of fasting
serum glucose (FSG) in diabetic patients (clopidogrel group
and placebo group) were signiﬁcantly elevated (P< 0.05) over
those of controls during the treatment period.
In patients treated with clopidogrel for 2 months, there was
signiﬁcant decrease in FSG level (P< 0.05) compared with
baseline value (7.495 ± 0.532 vs. 9.705 ± 0.743). The patients
of placebo treated group showed signiﬁcant increase in FSG
level after 2 months of treatment with placebo formula com-
pared with baseline value (9.33 ± 0.575 vs. 8.415 ± 0.418).
Table 2 demonstrated that the signiﬁcant decline in FSG level
after 2 months of clopidogrel treatment, as compared to base-
line level, occurred with remarkable percentage of decline in
FSG level (22.77%), while in the placebo treated group, signif-
icant increase in FSG level occurred after 2 months of placebo
therapy, and the percentage of increase was 10.87%.
Determination of serum insulin levels (Table 2) showed that
there were signiﬁcant elevations (P< 0.05) in the baseline va-
lue of insulin levels in clopidogrel treated group over those of
controls. In placebo treated group the serum insulin levels were
signiﬁcantly elevated (P< 0.05) over those of controls at the
baseline and after 2 months of treatment. There were signiﬁ-
cant decreases in insulin level (P< 0.05) after treatment com-
pared with baseline value in clopidogrel treated group
(8.981 ± 0.515 vs. 11.76 ± 1.00), with percentage of decline
(23.63%), while in placebo treated group, there were signiﬁ-
cant increase in insulin level after treatment compared with
baseline value (15.277 ± 1.254 vs. 13.838 ± 0.943) and per-
centage of increment (10.4%).
The values of QUICKI (Table 2) were signiﬁcantly different
(P< 0.05) in diabetic patients (clopidogrel group and placebo
group) as compared to controls at the baseline and after
2 months of treatment. In clopidogrel treated group, there was
signiﬁcant elevation in QUICKI values (P< 0.05) as compared
with baseline value (0.326 ± 0.005 vs. 0.295 ± 0.007) and per-
centage of increase (10.51%). In placebo treated group, therewas signiﬁcant decrease in baseline value (0.298 ± 0.004 vs.
0.304 ± 0.003) and the percentage of decline was 1.97%.
3.2. Effect of treatment with clopidogrel on oxidative stress
markers
A signiﬁcantly higher (P< 0.05) level of MDA was detected in
diabetic patients as compared to control during the treatment
period (Table 3). In patients treated with clopidogrel, there
was a signiﬁcant reduction in MDA level after 2 months of
treatment compared with the baseline value (2.09 ± 0.14 vs.
2.38 ± 0.18). In placebo treated group, there was a signiﬁcant
increase (P< 0.05) in the MDA level after 2 months of treat-
ment compared with baseline value (2.31 ± 0.13 vs.
2.02 ± 0.14). In clopidogrel group, a 12.18% decrease in
MDA level was reported and 14.36% increase in MDA level
was observed in placebo group.
Regarding reduced glutathione (GSH) level in serum, Table
3 showed that levels of GSH were signiﬁcantly lower than
those of controls during the treatment period. A signiﬁcant ele-
vation (P< 0.05) in GSH level after 2 months of treatment
with clopidogrel compared with baseline value had been dem-
onstrated (0.205 ± 0.006 vs. 0.153 ± 0.01).In patients treated
with placebo formula, there was no signiﬁcant change in
GSH level after 2 months of treatment compared with baseline
value (0.169 ± 0.003 vs. 0.186 ± 0.018). In clopidogrel group,
a 34.5% increase in GSH level was reported; while in placebo
group, 9.19% decrease was observed.
3.3. Effect of treatment with clopidogrel on AST and ALT
activities in serum
The data presented in Table 4 showed that in clopidogrel
group patients there was a signiﬁcant elevation (2.2%,
P< 0.05) in the level of AST after 2 months of treatment with
clopidogrel compared with the baseline value (23.23 ± 0.33 vs.
22.73 ± 0.42). However, the level of AST was signiﬁcantly
higher after treatment compared to control. In placebo group
there was no signiﬁcant change (P> 0.05) in the level of AST
after the treatment period and levels of AST do not show sig-
niﬁcant change compared to control group at base line and
after 2 months of treatment (Table 4).
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vel of ALT in clopidogrel group after 2 months of treatment
compared with the baseline value (19.27 ± 0.4 vs.
18.14 ± 0.43) The levels of ALT in both groups (clopidogrel
and placebo) at base line level and after treatment were not
different signiﬁcantly (P> 0.05) compared to control group
(Table 4).
4. Discussion
The present study investigated the effect of clopidogrel on gly-
cemic indices in type 2 diabetic patients treated with oral hypo-
glycemic agent (glibenclamide). Signiﬁcant reduction in FSG
was reported in patients treated with clopidogrel in addition
to the currently used oral hypoglycemic agent as compared
to the baseline FSG level (Table 2). Signiﬁcant reduction in
serum insulin level and improvement of insulin sensitivity
(QUICKI) was also observed in clopidogrel treated group after
2 months of treatment. These results could indicate that clop-
idogrel has glucose lowering effect and the FSG level in pla-
cebo treated group signiﬁcantly elevated after the same
course of treatment. This study also shows signiﬁcant increase
in insulin level and signiﬁcant decrease in insulin sensitivity
were also observed in placebo treated group (Table 2).
Whereas there is a signiﬁcant correlation between obesity
and insulin resistance (Kahn and Flier, 2000) it is not yet clear
how obesity leads to insulin resistance. On the other hand,
growing evidences suggest that insulin sensitivity of the whole
body is modulated by a large number of factors secreted by the
adipose tissue, which include insulin resistance-inducing fac-
tors such as, free fatty acids, TNF-a, IL-6 and resistin, as well
as insulin sensitizing factors such as adioponectin (Havel,
2004; Pittas et al., 2004). Del Aguila et al. have planned an
experimental study to determine whether TNF-a decreases
insulin responsiveness at the cellular level. Their study data
suggested that increases in TNF-a may cause insulin resistance
in skeletal muscle by inhibiting IRS-1 and IRS-2 mediated PI3
kinase activation, leading to impaired insulin-stimulated glu-
cose uptake (Del Aguila et al., 1999). Clopidogrel is a potent
oral antiplatelet agent that has the ability to suppress TNF-a
production (Dunzendorfer et al., 2002; Al-Bahrani et al.,
2007), and there is substantial evidence that therapy with clop-
idogrel leads to reduction in serum levels of inﬂammatory
markers including TNF-a across the spectrum of atherothrom-
botic disease (Steinhubl et al., 2007). The mechanism of glu-
cose lowering activity of clopidogrel is not clear but it could
be explained on the basis of clopidogrel inhibitory effect on
TNF-a production and this might cause improvement in insu-
lin sensitivity, increase in glucose utilization by peripheral tis-
sue and suppressed hepatic glucose production.
The present study clearly showed that the parameters of
oxidative stress were signiﬁcantly elevated in type 2 diabetic
patients, represented by the increased levels of serum MDA
compared to controls (Table 3). Most of clopidogrel treated
patients in this study demonstrated signiﬁcant reduction in
the serum MDA level. In placebo treated group the serum
MDA levels were signiﬁcantly elevated after the same course
of placebo treatment. These results suggest that clopidogrel
has antioxidant effect and they are compatible with some stud-
ies shown below. In patients with symptomatic coronary artery
disease, treatment with clopidogrel improved systemic endo-thelial function of nitric oxide bioavailability and reduced oxi-
dative stress. Enhanced production of oxygen derived free
radicals lead to impaired nitric oxide bioavailability and, there-
fore, reducing oxidative stress may be an important mecha-
nism by which clopidogrel exerts its beneﬁcial effect on nitric
oxide bioavailability (Heitzer et al., 2006). There is growing
evidence that excessive generation of highly reactive free radi-
cals, largely due to hyperglycemia, causes oxidative stress,
which further exacerbates the development and progression
of diabetes and its complication (Johansen et al., 2005). The
protective effect of clopidogrel on oxidant damage in a rat
model of acute ischemia was demonstrated. It has been ob-
served that ischemia–reperfusion injury caused by free radical
production (increase MDA level with a decrease in GSH level)
and pretreatment with clopidogrel prevented these changes
(Kanko et al., 2005). Clopidogrel increases the perfusion of tis-
sue by decreasing platelet and leukocyte adhesion and reducing
blood viscosity (Pasqualini et al., 2002). Furthermore, platelet
aggregation due to increased permeability in major organs dur-
ing reperfusion was reported to be prevented by clopidogrel
(Jeffrey et al., 1999), thus the inhibition of platelet aggregation
by preventing endothelial and leukocyte dysfunction might one
of the mechanisms of the drug to prevent the oxidative injury
(Dunzendorfer et al., 2002). Moreover the active metabolite of
clopidogrel has sulfhydryl group (thiol, SH group); the possi-
bility of chemical modiﬁcation of SH group has an important
regulative role. It is able to connect with compounds contain-
ing sulfur to produce sulfane sulfurs. The later compounds
contain a labile highly reactive sulfur atom at reduced oxida-
tion state and they have signiﬁcant antioxidant property (Iciek
and Wodek, 2001). This may suggest the mechanism responsi-
ble for the antioxidant effect of clopidogrel in this study.
It is found in the present study that serum GSH level was
shown to be signiﬁcantly reduced in type 2 diabetic patients
compared to controls (Table 3). Clopidogrel causes signiﬁcant
elevation in the serum GSH level after 2 months of treatment
while in the placebo treated group there is no signiﬁcant
change in the level of GSH after the same course of placebo
therapy. These results demonstrate that the drug improves
the antioxidant defense system represented by elevated GSH
levels and hence reduces the increased oxidative stress in dia-
betic patients. Although the exact mechanism of this effect is
not clearly understood, the results of this study suggest the
mediation of inhibited free radical production as one way be-
hind clopidogrel antioxidant (Kanko et al., 2005).
Table 4 showed that clopidogrel treatment resulted in a sig-
niﬁcant elevation in AST after 2 months while treatment with
placebo formula resulted in non-signiﬁcant changes. Regard-
ing ALT, signiﬁcant elevation was observed after treatment
with clopidogrel while in placebo treated group there was no
signiﬁcant change. Individuals with type 2 diabetes have a
higher incidence of liver function test abnormalities than indi-
viduals who do not have diabetes and chronic mild elevation of
transaminases is frequently found in type 2 diabetic patient
(Harris, 2005). The most common cause of elevated transami-
nases in diabetic patients is the excess intracellular fatty acid
found in insulin resistant state which is known to be directly
toxic to hepatocytes. Putative mechanisms include cell mem-
brane disruption at high concentration, mitochondrial dys-
function, toxin formation and activation and inhibition of
key steps in the regulation of metabolism and other potential
Beneﬁcial effects of clopidogrel on glycemic indices and oxidative stress in patients with type 2 diabetes 113explanation for elevated transaminases in insulin resistant state
is oxidative stress (Neuschwander-Tetri and Caldwell, 2003).
In this study the baseline levels of both AST and ALT of dia-
betic patients groups did not differ signiﬁcantly from those of
control. Since clopidogrel is activated by hydrolysis in the liver
to produce active and inactive metabolites, so it is necessary to
observe the hepatic function during the clopidogrel treatment
to detect any changes in the integrity of hepatocytes through
measuring AST and ALT activities. From the above resulted
results, it is found that clopidogrel caused signiﬁcant elevations
in the level of AST and ALT but this elevation remained with-
in the reference limited during the treatment period.
5. Conclusion
1. The adjuvant use of clopidogrel with oral hypoglycemic
agents (glibenclamide) increases insulin sensitivity and
improves glycemic homeostasis after short termof treatment.
2. The mechanism responsible for the clopidogrel induced
improvement of insulin sensitivity and glycemic control in
type 2 diabetic patients could possibly be related to antiox-
idant activity of clopidogrel and suppression of TNF-a pro-
duction, which is an important cause of insulin resistance.Acknowledgments
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